Table 1.
Characteristics of patients by implementation stage for a Pediatric Intestinal Surgery Enhanced Recovery After Surgery pathway.
| Pre-Implementation n=30 |
Early Implementation n=10 |
Full Implementation n=18 |
Non-enrolled n=8 |
p | |
|---|---|---|---|---|---|
| Age (Median, IQR) | 14 (9 – 16) | 17 (16 – 17) | 14 (8 – 16) | 12.5 (9 – 16) | 0.063 |
| Female (%) | 50 | 30 | 39 | 63 | 0.490 |
| Non-white (%) | 40 | 30 | 28 | 38 | 0.959 |
| ASA Class (Median, IQR) | 2 (2 – 3) | 2 (2 – 3) | 2 (2 – 3) | 2 (2 – 2) | 0.103 |
| Comorbidities (%) | |||||
| Cardiac | 13 | 0 | 0 | 0 | 0.279 |
| Immunologic | 30 | 20 | 67 | 57 | 0.029 |
| Nutritional | 17 | 10 | 22 | 0 | 0.700 |
| Endocrine | 3 | 0 | 11 | 0 | 0.697 |
| Operative Indication (%) | 0.273 | ||||
| Crohn’s / Unspecified IBD | 33 | 50 | 50 | 50 | |
| Ulcerative colitis | 10 | 30 | 6 | 0 | |
| Motility and Other Anatomic Disorder (incl. ostomies) | 57 | 20 | 39 | 50 | |
| Neoplasia | 0 | 0 | 6 | 0 | |
| Operative Approach (%) | 0.666 | ||||
| Open | 40 | 50 | 50 | 25 | |
| Laparoscopic | 60 | 50 | 50 | 75 | |
| Regional Anesthesia (%) | 20 | 70 | 83 | 63 | <0.001 |
Immunologic includes steroids, immunosuppressives, and biologic therapies.
IBD – inflammatory bowel disease